Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunological effects of hypomethylating agents.

Expert review of hematology - 1 Aug 2017

Lindblad Katherine E, Goswami Meghali, Hourigan Christopher S, Oetjen Karolyn A

Abstract excerpt

INTRODUCTION: Epigenetic changes resulting from aberrant methylation patterns are a recurrent observation in hematologic malignancies. Hypomethylating agents have a well-established role in the management of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. In addition to the direct effects of hypomethylating agents on cancer cells, there are several lines of evidence indicating a role...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunomodulation
Share to Killer Cells, Natural
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Dendritic Cells

Share to Epigenesis, Genetic

Share to Azacitidine

Share to Myelodysplastic Syndromes

Source

Open in PubMed Open full text

Identifiers

PMID: 28644756
DOI: 10.1080/17474086.2017.1346470
PMCID: PMC6071309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunological effects of hypomethylating agents.PMID 28644756Read ↗

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulationSemantic proximity Read ↗

The use of hypomethylating agents in the treatment of hematologic malignanciesSemantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

The DNA methylation landscape of hematological malignancies: an updateSemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the EpicenterSemantic proximity Read ↗

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancersSemantic proximity Read ↗

Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agentsSemantic proximity Read ↗

Epigenetic deregulation in myeloid malignanciesSemantic proximity Read ↗

The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacySemantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.